Impact van adjuvante anti-PD-1-immunotherapie op ovariële functie bij vrouwen met resectabel melanoom

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment and are increasingly used in the adjuvant and neoadjuvant setting for malignancies such as melanoma, which often affect younger adults. With improving survival, concerns about long-term safety, including potential effects on fertility, are growing.